Traws Pharma (FRA:0T2) Change In Inventory : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Change In Inventory?

Traws Pharma's change in inventory for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Traws Pharma's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Traws Pharma's change in inventory for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Traws Pharma's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Traws Pharma's Total Inventories for the quarter that ended in Dec. 2023 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Traws Pharma's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

Traws Pharma Change In Inventory Historical Data

The historical data trend for Traws Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Change In Inventory Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Traws Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Traws Pharma (FRA:0T2) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Traws Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Traws Pharma's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Traws Pharma's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.051
	=	0.00

Traws Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Traws Pharma (FRA:0T2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

ONTX:USA

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines